Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.41 |
| ▸ | HTR2C | P28335 | 3/20 | 0.37 |
| ▸ | HTR2B | P41595 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31411300 | 0.85 | HTR2A (0.43) | HTR2AHTR2CDRD2 | |
| SCHEMBL31411411 | 0.85 | HTR2A (0.37) | HTR2AHTR2CHTR2BALDH1A1TAAR1 | |
| Formic Acid SCHEMBL31411275 | 0.82 | HTR2A (0.43) | HTR2AHTR2CHTR2BTAAR1HTR1A | |
| SCHEMBL24694054 | 0.77 | HTR2A (0.52) | HTR2AHTR2CHTR2BHTR1A | |
| SCHEMBL30566021 | 0.77 | HTR2A (0.51) | HTR2AHTR2CHTR2BALDH1A1HTR1A | |
| SCHEMBL25249896 | 0.77 | HTR2A (0.51) | HTR2AHTR2CHTR2BALDH1A1HTR1A | |
| SCHEMBL31411439 | 0.76 | HTR2A (0.48) | HTR2AHTR2CDRD2 | |
| SCHEMBL31411383 | 0.75 | HTR1A (0.46) | HTR2AHTR2CHTR2BALDH1A1HTR1A | |
| SCHEMBL31411389 | 0.74 | HTR2A (0.43) | HTR2AALDH1A1HTR1AKDM4E | |
| SCHEMBL31411434 | 0.74 | HTR2A (0.44) | HTR2AALDH1A1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735425-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2026-05-06 | — | — | EP | disclosed |
| US-20250353818-A1 | Compounds | Psylo Pty Ltd (AU) | 2025-11-20 | — | — | US | disclosed |
| US-12428380-B2 | Compounds | Psylo Pty Ltd (AU) | 2025-09-30 | — | — | US | disclosed |
| US-20250214943-A1 | Compounds | Psylo Pty Ltd (AU) | 2025-07-03 | — | — | US | disclosed |
| WO-2025000053-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-01-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214943-A1 | Compounds | NLN, SLC18A2, PYGB | HTR2A 94/4885HTR2C 23/4885HTR2B 114/4885 |
| US-12428380-B2 | Compounds | NLN, SLC18A2, PYGB | HTR2A 94/4885HTR2C 23/4885HTR2B 114/4885 |
| US-20250353818-A1 | Compounds | NLN, SLC18A2, PYGB | HTR2A 94/4885HTR2C 23/4885HTR2B 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.